Obsidian Therapeutics (NASDAQ:OBX) Stock Moved Up to Hold by Wall Street Zen

Wall Street Zen upgraded shares of Obsidian Therapeutics (NASDAQ:OBX) from a sell rating to a hold rating in a research note published on Sunday morning,Wall Street Zen reports.

OBX has been the topic of several other research reports. Lifesci Capital assumed coverage on shares of Obsidian Therapeutics in a research report on Tuesday, August 18th. They set an “outperform” rating and a $43.00 price target on the stock. Zacks Research raised shares of Obsidian Therapeutics to a “hold” rating in a research note on Thursday, August 6th. William Blair initiated coverage on shares of Obsidian Therapeutics in a research report on Wednesday, September 9th. They set an “outperform” rating on the stock. Weiss Ratings assumed coverage on shares of Obsidian Therapeutics in a research note on Wednesday, September 2nd. They set a “sell (d-)” rating on the stock. Finally, TD Cowen started coverage on shares of Obsidian Therapeutics in a research report on Thursday, August 6th. They issued a “buy” rating for the company. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Obsidian Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $39.00.

Obsidian Therapeutics Price Performance

Shares of NASDAQ:OBX opened at $12.86 on Friday. Obsidian Therapeutics has a twelve month low of $12.16 and a twelve month high of $49.97.

About Obsidian Therapeutics

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian Therapeutics Inc is based in CAMBRIDGE, Mass.